Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 6/20 | 0.48 |
| ▸ | GRM5 | P41594 | 5/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117184 | 1.00 | GRM1 (0.48) | GRM1GRM5GPR119NAMPTSMPD3 | |
| SCHEMBL23411537 | 0.85 | QDPR (0.59) | GRM1GRM5NAMPTSMPD3CFTR | |
| SCHEMBL29891552 | 0.85 | QDPR (0.59) | GRM1GRM5NAMPTSMPD3CFTR | |
| SCHEMBL22358258 | 0.81 | GPR119 (0.41) | GRM1GRM5GPR119NAMPTPDK4 | |
| SCHEMBL20116505 | 0.78 | GPR119 (0.41) | GRM1GRM5GPR119NAMPTPDK4 | |
| SCHEMBL24265667 | 0.78 | GRM5 (0.47) | GRM1GRM5GPR119NAMPTSMPD3 | |
| SCHEMBL24266176 | 0.78 | ALOX5 (0.51) | GRM1GRM5NAMPTQDPRPDE4B | |
| SCHEMBL30424931 | 0.78 | ALOX5 (0.51) | GRM1GRM5NAMPTQDPRPDE4B | |
| SCHEMBL24265038 | 0.78 | GRM1 (0.53) | GRM1GRM5NAMPTCFTRQDPR | |
| SCHEMBL30309745 | 0.78 | GRM1 (0.53) | GRM1GRM5NAMPTCFTRQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | GRM1 540/4885GRM5 68/4885GPR119 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.